Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: Early results from the prospective randomized AMLSG 09-09 Phase III study
- Richard F. Schlenk
- , Peter Paschka
- , Julia Krzykalla
- , Daniela Weber
- , Silke Kapp-Schwoerer
- , Verena I. Gaidzik
- , Claudia Leis
- , Walter Fiedler
- , Thomas Kindler
- , Thomas Schroeder
- , Karin Mayer
- , Michael Lübbert
- , Mohammed Wattad
- , Katharina Götze
- , Heinz A. Horst
- , Elisabeth Koller
- , Gerald Wulf
- , Jan Schleicher
- , Martin Bentz
- , Richard Greil
- University Medical Center Ulm and Center of Excellence 'Metabolic Disorders'
- German Cancer Research Center
- University Hospital Heidelberg
- University Medical Center Hamburg-Eppendorf
- University Medical Center
- Heinrich-Heine-University
- University of Bonn and University Hospital Bonn
- University of Freiburg
- Hospital Essen-Werden
- University Hospital Schleswig-Holstein
- Medical University of Vienna
- University Medical Center
- Klinikum der Landeshauptstadt Stuttgart
- Städtisches Klinikum Karlsruhe
- University Children’s Hospital
- Klinikum Bremen-Mitte
- Braunschweig Municipal Hospital
- Klinikum am Gesundbrunnen
- Universitätsklinik Innsbruck
- Giessen University Hospital
- Hospital Elisabethinen Linz
- Malteser Krankenhaus St. Franziskus-Hospital
- Hannover Medical School
Research output: Contribution to journal › Article › peer-review
96
Scopus
citations